Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF ACCOUNTING OFFICER | July 15, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date July 15, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 29,062 |
Ending reported balance
After 2026-09-03 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-07-15 · Grant · Acquired 279 · Balance 27,697 F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Row 2 · 2026-09-01 · Exercise / conversion · Acquired 3,932 · Balance 31,629 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 2,558 · Balance 34,187 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,362 · Balance 36,549 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Exercise / conversion · Acquired 2,644 · Balance 39,193 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 6 · 2026-09-01 · Tax withholding · Disposed 5,531 · Balance 33,662 Row 7 · 2026-09-03 · Sale · Disposed 4,600 · Balance 29,062 F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,650 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 3,650 · Balance 3,650 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,931 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 2,644 · Balance 7,931 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 4,725 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,362 · Balance 4,725 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 2,557 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 2,558 · Balance 2,557 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 3,932 · Balance 0 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 14,600 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 14,600 · Balance 14,600 F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 04, 2024 Filed Oct 8, 2024 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-024885 · form4-10082024_081027.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · derivative · entry 10 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 774 Underlying: Class A Ordinary Share · 775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F7 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 329 | $26.74 | $8,797.46 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,435 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · derivative · entry 9 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,672 Underlying: Class A Ordinary Share · 2,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · derivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,865 Underlying: Class A Ordinary Share · 3,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 18,900 | $0.00 Strike: $26.74 | $0.00 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 Underlying: Class A Ordinary Share · 18,900 shares Expires 2034-08-31 F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,450 Underlying: Class A Ordinary Share · 9,450 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,755 | $26.74 | $73,668.70 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,989 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 6,490 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| July 15, 2024 Filed Sep 5, 2024 00:57 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Ordinary Share | 480 | $15.65 | $7,512.00 |
DisclosureSEC source: 0001415889-24-022861 · form4-09052024_120905.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,254 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2024 to July 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,932 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010505 · form4-04082024_090419.xml · derivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,190 Underlying: Class A Common Share · 3,932 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,666 | $17.90 | $29,821.40 |
DisclosureSEC source: 0001415889-24-010505 · form4-04082024_090419.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,328 Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 3,932 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010505 · form4-04082024_090419.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 9,450 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010505 · form4-04082024_090419.xml · derivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,122 Underlying: Class A Common Share · 9,450 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter. Read SEC document |
| April 04, 2024 Filed Apr 8, 2024 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 18,900 | $0.00 Strike: $18.06 | $0.00 |
DisclosureSEC source: 0001415889-24-010505 · form4-04082024_090419.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,900 Underlying: Class A Common Share · 18,900 shares Expires 2034-03-31 F2 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010084 · form4-04032024_090431.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,672 Underlying: Class A Common Share · 2,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, April 1, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,084 | $19.70 | $21,354.80 |
DisclosureSEC source: 0001415889-24-010084 · form4-04032024_090431.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,062 Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010084 · form4-04032024_090431.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 01, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 4,014 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · derivative · entry 9 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 4,014 shares Expires 2028-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 01, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 5,645 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · derivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 229 Underlying: Class A Common Share · 5,645 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 01, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 9,659 | $21.45 | $207,185.55 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · nonDerivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,588 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.45 to $21.49. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 01, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 4,014 | $13.88 | $55,714.32 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| March 01, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 5,645 | $8.83 | $49,845.35 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,233 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 5,126 | $0.00 Strike: $8.83 | $0.00 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,874 Underlying: Class A Common Share · 5,126 shares Expires 2029-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 5,126 | $21.79 | $111,695.54 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,588 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $21.56 to $21.90. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 5,126 | $8.83 | $45,262.58 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| January 15, 2024 Filed Mar 1, 2024 23:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 583 | $12.35 | $7,200.05 |
DisclosureSEC source: 0001415889-24-006170 · form4-03012024_110310.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,588 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2023 to January 15, 2024. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 16,670 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001415889-24-000608 · form4-01042024_040110.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,014 Underlying: Class A Common Share · 16,670 shares Expires 2028-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 16,670 | $19.17 | $319,563.90 |
DisclosureSEC source: 0001415889-24-000608 · form4-01042024_040110.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,005 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.13 to $19.43. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 16,670 | $13.88 | $231,379.60 |
DisclosureSEC source: 0001415889-24-000608 · form4-01042024_040110.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,675 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 9,316 | $0.00 Strike: $13.88 | $0.00 |
DisclosureSEC source: 0001415889-23-016827 · form4-12212023_091222.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,684 Underlying: Class A Common Share · 9,316 shares Expires 2028-08-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Common Share | 9,316 | $19.13 | $178,215.08 |
DisclosureSEC source: 0001415889-23-016827 · form4-12212023_091222.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,005 Read SEC document |
| December 19, 2023 Filed Dec 21, 2023 21:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 9,316 | $13.88 | $129,306.08 |
DisclosureSEC source: 0001415889-23-016827 · form4-12212023_091222.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 20:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-014037 · form4-10062023_081034.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350 Underlying: Class A Common Share · 175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. F2 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 20:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 52 | $16.01 | $832.52 |
DisclosureSEC source: 0001415889-23-014037 · form4-10062023_081034.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,005 Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 20:26 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-014037 · form4-10062023_081034.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · derivative · entry 9 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,549 Underlying: Class A Common Share · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 2, 2021. Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 228 | $17.76 | $4,049.28 |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,882 Read SEC document |
| September 02, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,110 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 20,459 | $0.00 Strike: $17.76 | $0.00 |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · derivative · entry 8 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,459 Underlying: Class A Common Share · 20,459 shares Expires 2033-08-31 F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,230 Underlying: Class A Common Share · 10,230 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,797 Underlying: Class A Common Share · 3,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,155 | $17.76 | $20,512.80 |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,336 Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 3,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,491 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| July 15, 2023 Filed Sep 6, 2023 23:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 581 | $12.35 | $7,175.35 |
DisclosureSEC source: 0001415889-23-013048 · form4-09062023_110926.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,558 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2023 to July 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,933 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-006445 · form4-04112023_090411.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,797 Underlying: Class A Common Share · 3,933 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,155 | $10.71 | $12,370.05 |
DisclosureSEC source: 0001415889-23-006445 · form4-04112023_090411.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,977 Read SEC document |
| April 10, 2023 Filed Apr 11, 2023 21:07 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 3,933 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-006445 · form4-04112023_090411.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 10,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005790 · form4-04032023_040420.xml · derivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,230 Underlying: Class A Common Share · 10,230 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.